1183P - Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk

Background

Participant perceptions of cancer screening reportedly vary by their degree of cancer risk and can impact future screening adherence. This may also be affected by MCED testing. Participants in the PATHFINDER study of MCED test implementation were asked about their intentions to participate in future cancer screening.

Methods

PATHFINDER enrolled adults ≥50 yrs into cohorts without or with additional cancer risk. Additional cancer risk participants had ≥1 factor: ≥100 cigarette smoking history, germline/hereditary cancer risk, prior cancer ≥3 yrs before enrollment. Participants were notified if the MCED test did or did not detect a cancer signal. PROs assessed after MCED test results disclosure are reported here. Adapted Multidimensional Impact of Cancer Risk Assessment (MICRA) assessed impact of MCED test result disclosure. Short Form 12-Item Health Survey (SF-12v2) Mental Component Summary assessed mental health. Single-item questions measured likely adherence to cancer screening and future MCED tests. Descriptive statistics were generated for PRO endpoints.

Results

In 6621 participants, median age = 63 yrs, Female = 64%, White = 92%. 92/6621 (1.4%) had a cancer signal detected (CSD), 6529/6621 (98.6%) had no cancer signal detected (NCSD). PRO responses at results disclosure for MICRA and SF-12v2 are in the table. Table: 1183P

SD, standard deviation. Higher scores indicate greater distress/uncertainty in MICRA and better health in SF-12v2. MICRA: Distress/uncertainty scores of 6/8 = “rarely” experiencing negative emotion; scores of 18/24 = “sometimes” experiencing negative emotion.Individual question results were: - How likely are you to follow cancer screening recommendations? 96% were Very/Likely - How likely are you to undergo a subsequent MCED test? 96% were Very/Likely

Conclusions

No notable differences in PROs were reported between cancer risk cohorts by signal detection status. Overall, participants reported low impact on levels of distress and uncertainty, although an increased impact was noted in participants with CSD compared to NCSD. Most participants undergoing MCED testing indicated they would continue to participate in routine cancer screening and be willing to undergo MCED testing again.

Clinical trial identification

NCT04241796.

Editorial acknowledgement

Writing and editorial assistance was provided by Neva C West, PhD (NeuroWest Solutions, Chicago, IL, USA).

Legal entity responsible for the study

Grail, Llc.

Funding

Grail, Llc.

Disclosure

C.A. Dilaveri: Financial Interests, Institutional, Research Funding: Grail Llc. E.A. Klein: Financial Interests, Personal, Full or part-time Employment: Grail Llc. K.C. Chung: Financial Interests, Personal, Full or part-time Employment: Grail Llc; Financial Interests, Personal, Stocks or ownership: Illumina, Bristol Myers Squibb, Gilead, Baxter, Bayer. M. Lopatin, E.T. Fung: Financial Interests, Personal, Full or part-time Employment: Grail Llc; Financial Interests, Personal, Stocks or ownership: Illumina. All other authors have declared no conflicts of interest.